NCT00000749View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (2)

37232

Vanderbilt Univ Hosp, Nashville

98144

Univ of Washington / Pacific Med Ctr, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biocine

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH